HKEX(HK:00388) 智通财经网·2025-10-30 11:03Core Insights - The 10th China Pharmaceutical Innovation and Investment Conference was successfully held in Nanjing from October 26 to 27, highlighting discussions on pharmaceutical R&D achievements and investment trends in the industry [1] Group 1: Market Dynamics - The Hong Kong Stock Exchange (HKEX) plays a crucial role in supporting the globalization of Chinese innovative pharmaceutical companies through its efficient and diverse international financing platform [1] - The healthcare sector in Hong Kong has seen significant IPO activity this year, ranking first globally in terms of fundraising in the new stock market [1] - As of now, Hong Kong has completed 12 biotech IPOs, raising a total of $1.3 billion, which positions it as the leading market for biotech fundraising globally [1] Group 2: Financing Trends - The biotech sector has experienced active refinancing transactions, with a total refinancing amount reaching $4.1 billion year-to-date, indicating a gradual recovery in market confidence [2] - The positive performance in the healthcare financing market is attributed to the continuous optimization of regulatory frameworks, the listing of high-quality innovative companies, and active investor participation [1]